Lexicon Pharmaceuticals’ (LXRX) Hold Rating Reiterated at Needham & Company LLC

Lexicon Pharmaceuticals (NASDAQ:LXRX)‘s stock had its “hold” rating reissued by research analysts at Needham & Company LLC in a research report issued on Monday,Benzinga reports.

Separately, HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Monday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $5.00.

Lexicon Pharmaceuticals Stock Performance

NASDAQ:LXRX traded down $0.35 during midday trading on Monday, reaching $0.35. The stock had a trading volume of 44,168,289 shares, compared to its average volume of 5,609,503. The stock has a market capitalization of $86.43 million, a P/E ratio of -0.47 and a beta of 1.04. Lexicon Pharmaceuticals has a 1-year low of $0.35 and a 1-year high of $2.83. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.45 and a quick ratio of 7.43. The firm’s fifty day simple moving average is $0.77 and its 200-day simple moving average is $1.18.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Intech Investment Management LLC bought a new position in shares of Lexicon Pharmaceuticals during the 3rd quarter worth about $115,000. Charles Schwab Investment Management Inc. raised its holdings in Lexicon Pharmaceuticals by 4.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,417,295 shares of the biopharmaceutical company’s stock valued at $2,225,000 after acquiring an additional 58,147 shares in the last quarter. FMR LLC lifted its position in shares of Lexicon Pharmaceuticals by 28.9% in the 3rd quarter. FMR LLC now owns 49,867,042 shares of the biopharmaceutical company’s stock worth $78,291,000 after acquiring an additional 11,179,919 shares during the period. BNP Paribas Financial Markets grew its holdings in shares of Lexicon Pharmaceuticals by 71.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 31,853 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 13,246 shares in the last quarter. Finally, BBR Partners LLC increased its position in shares of Lexicon Pharmaceuticals by 74.1% during the third quarter. BBR Partners LLC now owns 470,000 shares of the biopharmaceutical company’s stock valued at $738,000 after purchasing an additional 200,000 shares during the period. 74.70% of the stock is currently owned by institutional investors and hedge funds.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.